Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018174 · ClinicalTrials.gov registry record · Phase 3
Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
A Phase 3 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
NCT00018174: Completed Phase 3 study, sponsored by US Department of Veterans Affairs.
NCT00018174 is a Phase 3 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 247 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00018174, a Phase 3 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
Study Summary
This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
Interventions
- DRUG Placebo
- DRUG Fluoxetine
- BEHAVIORAL Behavioral group smoking cessation treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 1998-02 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
What the finished NCT00018174 record still lists
NCT00018174 is an interventional study that assigns participants to a tested intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00018174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00018174 about?
NCT00018174 is a clinical study titled "Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers". This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to ra...
What is the current status of trial NCT00018174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 1998-02. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00018174?
The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG), Behavioral group smoking cessation treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT00018174?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00018174's enrollment target sits among peer trials
247 1266th of 2000 higher than 734 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia